|
A Study of ddI in Patients with AIDS Who Become Sicker While Taking Zidovudine Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on A Study of ddI in Patients with AIDS Who Become Sicker While Taking Zidovudine conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Study of ddI in Patients with AIDS Who Become Sicker While Taking Zidovudine Clinical research trials and A Study of ddI in Patients with AIDS Who Become Sicker While Taking Zidovudine healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including A Study of ddI in Patients with AIDS Who Become Sicker While Taking Zidovudine. A Study of ddI in Patients with AIDS Who Become Sicker While Taking Zidovudine Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a A Study of ddI in Patients with AIDS Who Become Sicker While Taking Zidovudine clinical trial. Test subjects oftentimes recieve the best healthcare possible for their A Study of ddI in Patients with AIDS Who Become Sicker While Taking Zidovudine condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of ddI in Patients with AIDS Who Become Sicker While Taking Zidovudine  A Study of ddI in Patients with AIDS Who Become Sicker While Taking Zidovudine
A Study of ddI in Patients with AIDS Who Become Sicker While Taking Zidovudine
For Condition: HIV Infections,Leukoencephalopathy, Progressive Multifocal
Status: No longer recruiting
Sponsor(s): Bristol-Myers Squibb ,
Synopsis: The objective of this open-label study regimen is to make didanosine (ddI) available to patients with AIDS who are clinically deteriorating on zidovudine (AZT) and cannot enter the Phase II ddI programs due to protocol exclusion or geographic location.
Details:
Eligibility:
Study Type: Interventional, Treatment, Open Label
Minimum Age/Maximum Age: 12 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Concurrent medications for treatment of complications of AIDS are allowed. - Aerosolized pentamidine. - Phenytoin, but with caution. - Note: - Extreme caution should be exercised in the use of didanosine (ddI) in any patient receiving concurrent therapies, particularly those receiving other nucleosides (e.g., ganciclovir), drugs with toxicities similar to those observed with ddI (list included under concomitant medications section of protocol), and other drugs with significant toxicities, including many drugs used for treatment of major opportunistic infections. Patients must be: Not suitable for entry into ddI phase II studies by reason of inclusion or exclusion criteria or by reason of geographic location. Able to provide signed informed consent (parent/guardian as appropriate). Available for monthly follow-up while taking ddI. Meet required baseline laboratory values within 14 days prior to initial drug dosing. Note: - Extreme caution should be exercised in the use of ddI in any patient receiving concomitant therapies, particularly those receiving other nucleosides (e.g., ganciclovir), drugs with toxicities similar to those observed with ddI (list included under concomitant medications section of protocol), and other drugs with significant toxicities, including many drugs used for treatment of major opportunistic infections. Caution should also be exercised in a patient having intractable diarrhea or patients following a low-sodium diet. Physicians caring for these patients must perform clinical and laboratory evaluations every 7-10 days for the first 2 months of ddI therapy. Should any adverse effect of any severity be detected during this period of intensive clinical and laboratory monitoring, the physician must call Bristol-Myers Squibb (1-800-662-7999). If the patient continues ddI therapy, Bristol-Myers Squibb will require submission of follow-up and adverse experience report forms every 10 days. Although data are not available to fully assess the risks associated with the use of ddI in high-risk patients (for example, patients with preexisting disorders of body systems known to be adversely affected by ddI, particularly those with history of peripheral neuropathy, pancreatitis, seizure disorder, cardiac abnormalities, gout, and significant elevations of liver function test results), all such patients must have clinical and laboratory evaluations performed every 10 days and results submitted to Bristol-Myers Squibb on the case report forms provided. Exclusion Criteria Co-existing Condition: Patients with any one of the following criteria are excluded: - Received therapy in the preceding 15 days with any other antiretroviral except zidovudine (AZT). - Taking AZT concomitantly. - Acute pancreatitis. - Poorly controlled seizure disorder. - Taking phenytoin concomitantly. - Grade B or greater peripheral neuropathy. Concurrent Medication: Excluded: - Zidovudine (AZT). Patients with any one of the following criteria are excluded: - Received therapy in the preceding 15 days with any other antiretroviral except zidovudine (AZT). - Taking AZT concomitantly. - Taking phenytoin concomitantly. - Acute pancreatitis. - Poorly controlled seizure disorder. - Grade B or greater peripheral neuropathy. Prior Medication: Excluded within 15 days of study entry: - Any antiretroviral except zidovudine (AZT). Required: - Zidovudine (AZT).
Total Enrollment:
Location and Contact Information:
Bristol - Myers Squibb Co
Princeton, New Jersey, 085434500
United States
Additional Information:
Study ID Numbers: 039A; 454-999-002
Study Start Date:
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002274
Other Hiv Infections Studies:
1. A Randomized, Unblinded Trial of Zidovudine Versus ddC in the Treatment of Patients Status Post PCP Who Received Long-Term Zidovudine Therapy in Protocol ACTG 002
2. Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy
3. Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients
4. Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen
5. Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Primary and Chronic HIV-Infected Patients
Related Studies:
Other HIV Infections Clinical Trials
Other New Jersey Clinical Trials
Other Princeton Clinical Trials
A Study of ddI in Patients with AIDS Who Become Sicker While Taking Zidovudine
|
|
|
|
|
|
|
|
